Cancer Voices Australia v Myriad Genetics Inc

Link copied
Case Copied 71 min read

FEDERAL COURT OF AUSTRALIA

Cancer Voices Australia v Myriad Genetics Inc [2013] FCA 65

Citation: Cancer Voices Australia v Myriad Genetics Inc [2013] FCA 65
Parties: CANCER VOICES AUSTRALIA and YVONNE D'ARCY v MYRIAD GENETICS INC and GENETIC TECHNOLOGIES LIMITED (ABN 17 009 212 328)
File number: NSD 643 of 2010
Judge: NICHOLAS J
Date of judgment: 15 February 2013
Corrigendum: 25 February 2013
Catchwords:

PATENTS – Patent including claims for isolated DNA and RNA (nucleic acid) – whether claims to composition comprising naturally occurring DNA and RNA that has been isolated are for a manner of manufacture for purposes of s 18(1)(a) of Patents Act 1990 (Cth) – where isolated DNA and RNA has been extracted from cells removed from human body and purged of other biological material with which it is associated in the cell – whether isolation of naturally occurring DNA and RNA results in an artificial state of affairs with a discernible effect – whether claims to isolated DNA and RNA are to a “mere discovery” and therefore not patentable – whether claims to isolated DNA and RNA are to a “product of nature” and therefore not patentable – whether order revoking challenged claims should be made

Held: each of challenged claims is to a manner of manufacture – requirements of s 18(1)(a) of Patents Act 1990 (Cth) satisfied – where non-compliance with requirements of s 18(1)(a) sole ground relied upon in support of application for orders revoking challenged claims – application dismissed with costs.

Legislation: Patents Act 1990 (Cth) s 18
Statute of Monopolies s 6
Patents Act 1949 (UK)
Patents Bill 1990 (Cth)
Patent Amendment (Human Genes and Biological Materials) Bill 2010 (Cth)
Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (Cth)
Cases cited:

Advanced Building Systems Pty Limited v Ramset Fasteners (Aust) Pty Limited (1998) 194 CLR 171
American Cyanamid Company v Upjohn Company [1971] RPC 425
CCOM Pty Ltd v Jiejing Pty Ltd (1994) 51 FCR 260
Diamond v Chakrabarty 447 US 303
Festo Corp. v Shoketsu Kinzoku Kogyu Kabushiki Co. 535 US 722, 739 (2002)
Funk Bros. Seed Co. v Kalo Inoculant Co. (1948) 333 US 127
Genentech Inc’s Patent [1987] RPC 553
Grain Pool of Western Australia v Commonwealth of Australia (2000) 202 CLR 479
Joos v Commissioner of Patents (1972) 126 CLR 611
Kirin-Amgen Inc v Board of Regents of University of Washington (1995) 33 IPR 557
Kirin-Amgen Inc v Hoechst Marion Roussel Ltd [2005] RPC 169
Mayo Collaborative Services v Prometheus Laboratories Inc 132 SCt 1289 (2012)
National Research Development Corporation v Commissioner of Patents (1959) 102 CLR 252
Re GEC’s Application (1943) 60 RPC 1
Reynolds v Herbert Smith & Co Ltd (1903) 20 RPC 123
The Association for Molecular Pathology & Ors v United States Patent and Trademark Officeand Myriad Genetics Inc 653 F3d 1329 (2011)
The Association for Molecular Pathology & Ors v United States Patent and Trademark Officeand Myriad Genetics Inc 689 F3d 1303 (2012)

Andrew Stewart, Phillip Griffith and…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Cancer Voices Australia v Myriad Genetics Inc and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2013] FCA 65
Decision Date

CaseChat Overview and Summary

Cancer Voices Australia challenged the validity of certain patent claims held by Myriad Genetics Inc, which related to isolated DNA and RNA. The dispute centred on whether the claims to isolated nucleic acids were patentable under section 18(1)(a) of the Patents Act 1990 (Cth), which requires that the subject matter of a patent be a "manner of manufacture" and not a "discovery" or "product of nature". The applicants argued that the isolated nucleic acids were not patentable because they were naturally occurring and their isolation did not create an artificial state of affairs with a discernible effect. The respondents, on the other hand, argued that the isolated nucleic acids were patentable because their isolation constituted a manner of manufacture under the Act.

The court found that the isolated nucleic acids were patentable subject matter under section 18(1)(a) of the Act. The court held that the isolation of naturally occurring DNA and RNA resulted in an artificial state of affairs with a discernible effect, and that the claims to isolated nucleic acids were to a manner of manufacture and not to a mere discovery or product of nature. The court also noted that the Act does not specifically preclude the grant of a patent for isolated DNA or RNA sequences, and that it was not the intention of Parliament to deal with the issue of "gene patenting" by way of express statutory exclusion. The court further held that the subject matter of the disputed claims satisfied the second essential quality of an invention, which is "economic significance".

The court dismissed the application to revoke the challenged claims with costs. The applicants were given 21 days to file a notice of appeal, after which the costs order would become effective. The court's decision provides guidance on the patentability of isolated nucleic acids in Australia and clarifies the scope of section 18(1)(a) of the Act.

Orders

Orders of the court

1. The amended application be dismissed.

2. The applicants pay the respondents’ costs.

3. Subject to any further order, order 2 is stayed for 21 days and, if a notice of appeal is filed within that time, until the determination of the appeal.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011

Background

Background to the litigation

There are a number of preliminary observations to make concerning the issues in this proceeding:·It is common ground that the disputed claims are invalid if they encompass any isolated nucleic acid that does not constitute patentable subject matter. This is because the validity of the disputed claims must be assessed across their full breadth. Thus, the fact that the disputed claims extend to forms of nucleic acid that have been synthesized in the laboratory (cDNA) will not save them if, as the applicants contend, they also extend to forms of nucleic acid that are not patentable.·The case was for the most part conducted on the basis that all of the disputed claims will stand or fall together, and that if claim 1 is invalid because it includes non-patentable subject matter, claims 2 and 3 will also be invalid for the same reason. However, while claim 1 is directed to “isolated nucleic acid” encompassing both DNA and RNA, claims 2 and 3, which are dependent on claim 1, are limited to “isolated nucleic acid ... which is a DNA”.·The applicants challenge the disputed claims solely on the basis that they include non-patentable subject matter. No other ground of invalidity (including lack of novelty, lack of inventive step, lack of utility or lack of fair basis) is relied upon by the applicants. In particular, it may be assumed that the inventors were the first to isolate the nucleic acids referred to in the disputed claims.·The applicants accepted that the subject matter of each of the disputed claims satisfied the second of the essential qualities of an invention referred to by the High Court in NRDC. In this regard, the applicants accepted that the subject matter of the disputed claims was of “economic significance”. ·Although the applicants initially sought to rely upon s 18(2) of the Act, they ultimately abandoned any argument based upon it. Even so, s 18(2) of the Act is still relevant to the issues in the case and it will be necessary to say more about it later in these reasons. SCIENTIFIC BACKGROUND Expert Witnesses There was expert evidence given by three eminent experts. Dr Suthers (called by the applicants) and Professor Brown (called by the respondents) were both cross-examined. Professor Rasko (also called by the respondents) was not cross-examined. I found Dr Suthers and Professor Brown to be impressive witnesses. Although I did not have the opportunity to see Professor Rasko in the witness box (because he was not required for cross-examination), I found his affidavit extremely helpful. All three witnesses gave evidence that provided important background to the field of the invention. Unless otherwise indicated, the statements appearing in this section of these reasons comprise findings based upon expert evidence that was not in dispute.The eukaryotic cell The human body is a multi-cellular eukaryotic organism which consists of a large number of different types of eukaryotic cells. Eukaryotic cells are cells which contain a membrane-bound nucleus. These cells communicate and co-operate with each other for the common good of the organism. The process by which cells reproduce is known as “cell division”. This process is binary in the sense that each cell is able to separate into two daughter cells.

Evidence

Evidence Before The Court

Decision

Reasons for decision

It is important to observe, even though it may go without saying, that the Act does not include any provision that specifically precludes the grant of a patent for an isolated DNA or RNA sequence. In particular, s 18(2) of the Act provides only that “human beings, and biological processes for their generation” are not patentable. A proposal that the Patents Bill 1990 (Cth) be amended to include a similar provision that would have treated DNA and RNA in the same way was not adopted. The inference to be drawn is that it was not the intention of Parliament at the time the Act was passed to deal with the issue of “gene patenting” by way of express statutory exclusion along the lines of s 18(2), but to leave it to the Courts to apply the law as settled in the NRDC case and other relevant authorities. Early decisions of the Australian Patent Office on the patentability of isolated DNA sequences Until now, there have been no judicial decisions in this country which have considered the patentability of isolated DNA or RNA sequences. However, there have been a number of decisions issued by the Australian Patent Office which have referred to the point. The first reported decision of the Australian Patent Office allowing a claim to isolated DNA was made in the context of an opposition proceeding in the matter of Kirin-Amgen Inc v Board of Regents of University of Washington (1995) 33 IPR 557. In that matter, the Deputy Commissioner of Patents (Mr D Herald) noted that no objection had been taken by the opponent to various claims in the opposed patent application on the ground that their subject matter involved the “mere discovery” of the DNA sequence encoding erythropoiten. Nevertheless, Mr Herald, having raised the issue himself, said (at 569):The present invention fundamentally relies upon the discovery of the DNA sequence encoding erythropoietin. In my view a claim directed to naturally occurring DNA characterised by specifying the DNA coding for a portion of that molecule would likely be claiming no more than a discovery per se and not be a manner of manufacture.The present specification contains claims to DNA sequences, in two categories:•Claims 14, 17, 18, and 55, which claim a “purified and isolated” sequence limited to that specified in tables V or VI, or limited to being “essentially” the sequence encoding erythropoietin. These claims are directed to a molecule which is a fragment of the full chromosome. They do not claim the naturally occurring chromosome, or any other naturally occurring entity. By being directed to a purified and isolated DNA sequence they claim “an artificially created state of affairs’’.•Claim 33 claims:A DNA sequence coding for a polypeptide analogue of naturally-occurring erythropoietin.and claim 34 claims:A DNA sequence coding for …specifying human erythropoietin with a range of substitutions or deletions.Both claims include within their scope a full length chromosome containing the relevant sequence, because they are not restricted to a “purified and isolated” sequence. However, both claims are directed to molecules which have been deliberately changed from the naturally occurring form - ie they are directed to artificially created states of affairs.I also observe that an objection of manner of manufacture might arise if the claims were directed to a mere chemical curiosity; but that is plainly not the case with this invention.Accordingly, I am satisfied that an objection of manner of manufacture does not apply to any of the claims.

Ratio Decidendi

Legal Principle Established

Section 18(1A) of the Act is concerned with innovation patents. It is not necessary to set s 18(1A) out. As with standard patents, the invention the subject of a claim in an innovation patent must be a manner of manufacture. Section 18(1A) is followed by s 18(2)-(4). They provide:(2)Human beings, and the biological processes for their generation, are not patentable inventions.(3)For the purposes of an innovation patent, plants and animals, and the biological processes for the generation of plants and animals, are not patentable inventions.(4)Subsection (3) does not apply if the invention is a microbiological process or a product of such a process.National Research Development Corporation v Commissioner of Patents The starting point for my consideration of the legal issues that arise is the High Court’s decision in the NRDC case. The case was described by Barwick CJ in Joos v Commissioner of Patents (1972) 126 CLR 611 at 616 as a “watershed” in this area of law, and in Grain Pool of Western Australia v Commonwealth of Australia (2000) 202 CLR 479 at para [45] Gleeson CJ, Gaudron, McHugh, Gummow, Hayne and Callinan JJ referred to it as a “celebrated judgment”. As the Full Court (Spender, Gummow and Heerey JJ) explained in CCOM Pty Ltd v Jiejing Pty Ltd (1994) 51 FCR 260 (at 289): In Australia, when the 1952 Act was replaced by the 1990 Act, the new British legislation was not followed. There was in s 18(2) an express exclusion from patentable inventions of human beings and biological processes for their generation. Beyond that the legislature left the matter, in terms of s 18(1)(a), to rest with the concept of manner of manufacture within the meaning of s 6 of the Statute of Monopolies, as developed by the Courts, notably in the NRDC case. This was a matter of deliberate legislative choice. There were three claims in issue in the NRDC case. All were method claims concerned with the use of a known chemical composition (“herbicide”) in the eradication or control of weeds. The first claim was directed to the use of the herbicide in the eradication of weeds from areas containing leguminous fodder crops of the Trifolium and Medicago families, as well as celery and parsnip. The second and third claims were directed to the use of the herbicide to control charlock, creeping thistle and annual nettle weeds in different crop varieties. The examiner raised objections to these claims on the basis that none was directed to any manner of manufacture. There were two arguments relied upon by the examiner in support of that conclusion. The first was that the claims involved “the mere use of known substances” and the second was that the use of these substances did “not result in any vendible product”. Both arguments relied upon by the examiner were also relied upon by the Commissioner of Patents (the Commissioner) in the High Court. The first was rejected by the High Court on the basis that the invention as claimed involved a new and inventive use of a known chemical composition. The second was also rejected by the High Court.